Microbix Biosystems Inc. (MBX.TO)
CAD 0.36
(-5.26%)
CAD 0.36
(-5.26%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 16.51 Million CAD | -13.43% |
| 2022 | 19.07 Million CAD | 2.6% |
| 2021 | 18.59 Million CAD | 76.66% |
| 2020 | 10.52 Million CAD | -21.53% |
| 2019 | 13.41 Million CAD | 7.21% |
| 2018 | 12.51 Million CAD | 22.82% |
| 2017 | 10.18 Million CAD | 7.03% |
| 2016 | 9.51 Million CAD | 7.25% |
| 2015 | 8.87 Million CAD | 5.68% |
| 2014 | 8.39 Million CAD | 10.85% |
| 2013 | 7.57 Million CAD | 13.57% |
| 2012 | 6.66 Million CAD | 7.09% |
| 2011 | 6.22 Million CAD | -3.64% |
| 2010 | 6.46 Million CAD | 6.26% |
| 2009 | 6.08 Million CAD | 21.81% |
| 2008 | 4.99 Million CAD | 23.33% |
| 2007 | 4.04 Million CAD | 11.11% |
| 2006 | 3.64 Million CAD | -16.74% |
| 2005 | 4.37 Million CAD | 7.6% |
| 2004 | 4.06 Million CAD | 42.88% |
| 2003 | 2.84 Million CAD | 1.43% |
| 2002 | 2.8 Million CAD | -6.09% |
| 2001 | 2.98 Million CAD | 60.98% |
| 2000 | 1.85 Million CAD | 16.03% |
| 1999 | 1.6 Million CAD | -48.39% |
| 1998 | 3.1 Million CAD | 14.81% |
| 1997 | 2.7 Million CAD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 8.4 Million CAD | 97.17% |
| 2024 Q2 | 5.63 Million CAD | -33.0% |
| 2024 Q3 | 5.05 Million CAD | -10.18% |
| 2023 Q3 | 5.53 Million CAD | 31.1% |
| 2023 Q2 | 4.21 Million CAD | 68.59% |
| 2023 Q1 | 2.5 Million CAD | -42.2% |
| 2023 FY | 16.51 Million CAD | -13.43% |
| 2023 Q4 | 4.26 Million CAD | -22.89% |
| 2022 Q2 | 4.88 Million CAD | 0.51% |
| 2022 Q1 | 4.85 Million CAD | -13.75% |
| 2022 FY | 19.07 Million CAD | 2.6% |
| 2022 Q4 | 4.32 Million CAD | -13.61% |
| 2022 Q3 | 5.01 Million CAD | 2.67% |
| 2021 Q2 | 4.35 Million CAD | 37.88% |
| 2021 FY | 18.59 Million CAD | 76.66% |
| 2021 Q3 | 5.45 Million CAD | 25.22% |
| 2021 Q4 | 5.62 Million CAD | 3.26% |
| 2021 Q1 | 3.15 Million CAD | 16.7% |
| 2020 Q3 | 2.89 Million CAD | 0.83% |
| 2020 Q4 | 2.7 Million CAD | -6.65% |
| 2020 FY | 10.52 Million CAD | -21.53% |
| 2020 Q1 | 2.04 Million CAD | -42.96% |
| 2020 Q2 | 2.87 Million CAD | 40.47% |
| 2019 Q1 | 2.46 Million CAD | -27.4% |
| 2019 Q2 | 4.25 Million CAD | 72.85% |
| 2019 FY | 13.41 Million CAD | 7.21% |
| 2019 Q4 | 3.58 Million CAD | 15.32% |
| 2019 Q3 | 3.11 Million CAD | -26.87% |
| 2018 Q3 | 3.23 Million CAD | 7.83% |
| 2018 Q2 | 3 Million CAD | 3.97% |
| 2018 Q1 | 2.88 Million CAD | 2.57% |
| 2018 Q4 | 3.38 Million CAD | 4.77% |
| 2018 FY | 12.51 Million CAD | 22.82% |
| 2017 FY | 10.18 Million CAD | 7.03% |
| 2017 Q1 | 1.95 Million CAD | -43.74% |
| 2017 Q4 | 2.81 Million CAD | 1.44% |
| 2017 Q3 | 2.77 Million CAD | 4.79% |
| 2017 Q2 | 2.64 Million CAD | 35.55% |
| 2016 Q4 | 3.47 Million CAD | 54.02% |
| 2016 FY | 9.51 Million CAD | 7.25% |
| 2016 Q1 | 1.06 Million CAD | -49.7% |
| 2016 Q2 | 2.72 Million CAD | 156.7% |
| 2016 Q3 | 2.25 Million CAD | -17.45% |
| 2015 Q2 | 2.54 Million CAD | 27.51% |
| 2015 Q1 | 1.99 Million CAD | -15.28% |
| 2015 Q4 | 2.11 Million CAD | -4.73% |
| 2015 Q3 | 2.21 Million CAD | -12.81% |
| 2015 FY | 8.87 Million CAD | 5.68% |
| 2014 Q3 | 2.03 Million CAD | -1.6% |
| 2014 FY | 8.39 Million CAD | 10.85% |
| 2014 Q4 | 2.35 Million CAD | 15.49% |
| 2014 Q2 | 2.07 Million CAD | 7.53% |
| 2014 Q1 | 1.92 Million CAD | -21.91% |
| 2013 Q4 | 2.46 Million CAD | 29.49% |
| 2013 Q2 | 2.1 Million CAD | 132.57% |
| 2013 Q1 | 904.41 Thousand CAD | -52.02% |
| 2013 Q3 | 1.9 Million CAD | -9.35% |
| 2013 FY | 7.57 Million CAD | 13.57% |
| 2012 FY | 6.66 Million CAD | 7.09% |
| 2012 Q3 | 2.84 Million CAD | 49.98% |
| 2012 Q2 | 1.89 Million CAD | 28.65% |
| 2012 Q1 | 1.47 Million CAD | -31.03% |
| 2012 Q4 | 1.88 Million CAD | -33.75% |
| 2011 Q4 | 2.13 Million CAD | 41.02% |
| 2011 Q2 | 1.76 Million CAD | 116.8% |
| 2011 Q1 | 812.69 Thousand CAD | -63.4% |
| 2011 Q3 | 1.51 Million CAD | -13.96% |
| 2011 FY | 6.22 Million CAD | -3.64% |
| 2010 Q2 | 1.83 Million CAD | 49.3% |
| 2010 Q4 | 2.22 Million CAD | 87.44% |
| 2010 FY | 6.46 Million CAD | 6.26% |
| 2010 Q1 | 1.22 Million CAD | -19.0% |
| 2010 Q3 | 1.18 Million CAD | -35.3% |
| 2009 Q3 | 1.39 Million CAD | -11.39% |
| 2009 Q2 | 1.57 Million CAD | -2.26% |
| 2009 Q1 | 1.6 Million CAD | 27.53% |
| 2009 FY | 6.08 Million CAD | 21.81% |
| 2009 Q4 | 1.51 Million CAD | 8.83% |
| 2008 Q3 | 1.51 Million CAD | 28.6% |
| 2008 Q4 | 1.25 Million CAD | -16.97% |
| 2008 Q2 | 1.17 Million CAD | 13.78% |
| 2008 Q1 | 1.03 Million CAD | -11.51% |
| 2008 FY | 4.99 Million CAD | 23.33% |
| 2007 Q4 | 1.17 Million CAD | 4.0% |
| 2007 Q3 | 1.12 Million CAD | 4.53% |
| 2007 Q2 | 1.07 Million CAD | 60.29% |
| 2007 Q1 | 672.48 Thousand CAD | -0.43% |
| 2007 FY | 4.04 Million CAD | 11.11% |
| 2006 Q4 | 675.4 Thousand CAD | -30.98% |
| 2006 Q3 | 978.58 Thousand CAD | 14.68% |
| 2006 Q2 | 853.34 Thousand CAD | -24.94% |
| 2006 FY | 3.64 Million CAD | -16.74% |
| 2006 Q1 | 1.13 Million CAD | 17.89% |
| 2005 Q2 | 1.03 Million CAD | -13.06% |
| 2005 FY | 4.37 Million CAD | 7.6% |
| 2005 Q1 | 1.19 Million CAD | -29.14% |
| 2005 Q4 | 964.32 Thousand CAD | -18.46% |
| 2005 Q3 | 1.18 Million CAD | 14.04% |
| 2004 FY | 4.06 Million CAD | 42.88% |
| 2004 Q2 | 834.56 Thousand CAD | 6.44% |
| 2004 Q3 | 765.63 Thousand CAD | -8.26% |
| 2004 Q4 | 1.68 Million CAD | 119.84% |
| 2004 Q1 | 784.1 Thousand CAD | -17.32% |
| 2003 Q3 | 600.86 Thousand CAD | -19.25% |
| 2003 Q2 | 744.12 Thousand CAD | 34.45% |
| 2003 Q1 | 553.44 Thousand CAD | -22.25% |
| 2003 FY | 2.84 Million CAD | 1.43% |
| 2003 Q4 | 948.37 Thousand CAD | 57.84% |
| 2002 Q2 | 751.9 Thousand CAD | 59.04% |
| 2002 Q4 | 711.86 Thousand CAD | -18.18% |
| 2002 Q3 | 870.02 Thousand CAD | 15.71% |
| 2002 FY | 2.8 Million CAD | -6.09% |
| 2002 Q1 | 472.79 Thousand CAD | -29.61% |
| 2001 Q4 | 671.71 Thousand CAD | -6.09% |
| 2001 Q3 | 715.23 Thousand CAD | -4.69% |
| 2001 Q2 | 750.4 Thousand CAD | -12.25% |
| 2001 Q1 | 855.19 Thousand CAD | 53.67% |
| 2001 FY | 2.98 Million CAD | 60.98% |
| 2000 FY | 1.85 Million CAD | 16.03% |
| 2000 Q4 | 556.51 Thousand CAD | 11.3% |
| 2000 Q3 | 500 Thousand CAD | 25.0% |
| 2000 Q2 | 400 Thousand CAD | 0.0% |
| 2000 Q1 | 400 Thousand CAD | -20.0% |
| 1999 Q2 | 200 Thousand CAD | -50.0% |
| 1999 Q3 | 500 Thousand CAD | 150.0% |
| 1999 Q1 | 400 Thousand CAD | 300.0% |
| 1999 Q4 | 500 Thousand CAD | 0.0% |
| 1999 FY | 1.6 Million CAD | -48.39% |
| 1998 Q4 | 100 Thousand CAD | -93.75% |
| 1998 Q3 | 1.6 Million CAD | 60.0% |
| 1998 Q2 | 1 Million CAD | 150.0% |
| 1998 FY | 3.1 Million CAD | 14.81% |
| 1998 Q1 | 400 Thousand CAD | -20.0% |
| 1997 Q1 | 600 Thousand CAD | 0.0% |
| 1997 Q4 | 500 Thousand CAD | -44.44% |
| 1997 Q3 | 900 Thousand CAD | 28.57% |
| 1997 Q2 | 700 Thousand CAD | 16.67% |
| 1997 FY | 2.7 Million CAD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Appili Therapeutics Inc. | 827.4 Thousand CAD | -1895.968% |
| Eupraxia Pharmaceuticals Inc. | - CAD | -Infinity% |
| Helix BioPharma Corp. | - CAD | -Infinity% |
| Medicenna Therapeutics Corp. | - CAD | -Infinity% |
| Satellos Bioscience Inc. | - CAD | -Infinity% |
| Oncolytics Biotech Inc. | - CAD | -Infinity% |
| Sernova Corp. | - CAD | -Infinity% |